

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
01 September 2022 (01.09.2022)



(10) International Publication Number
WO 2022/180271 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
A61P 35/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2022/054993

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(22) International Filing Date:
28 February 2022 (28.02.2022)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21159698.6 26 February 2021 (26.02.2021) EP
63/166,339 26 March 2021 (26.03.2021) US
63/274,709 02 November 2021 (02.11.2021) US
21211114.0 29 November 2021 (29.11.2021) EP

(71) Applicant: **LAVA THERAPEUTICS N.V.** [NL/NL];
Yalelaan 60, 3584 CM Utrecht (NL).

(72) Inventors: **ROOVERS, Robertus Cornelis**; Yalelaan 60,
3584 CM Utrecht (NL). **VAN DER VLIET, Johannes
Jelle**; Yalelaan 60, 3584 CM Utrecht (NL). **LUTJE
HULSIK, David**; Yalelaan 60, 3584 CM Utrecht (NL).
PARREN, Paul Willem Henri Ida; Yalelaan 60, 3584
CM Utrecht (NL). **RUBEN, Jurjen Matthijs**; Yalelaan 60,
3584 CM Utrecht (NL). **MOUSSET, Charlotte Merette**;
Yalelaan 60, 3584 CM Utrecht (NL).

(74) Agent: **NEDERLANDSCH OCTROOIBUREAU**;
P.O.Box 29720, 2502 LS The Hague (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: Antibodies that bind CD123 and gamma-delta T cell receptors

(57) Abstract: The present invention relates to antibodies capable of binding human CD123 and capable of binding the Vδ2 chain of a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

WO 2022/180271 A1